July 18, 2006
A new study of AMBIEN CR, a controlled-release formula prescription sleep medication approved by the Food and Drug Administration (FDA) for sleep maintenance and sleep induction, found that the drug demonstrated significant improvements in total sleep time (TST), sleep onset latency (SOL), wake time after sleep onset (WASO), sleep quality, and number of awakenings versus placebo.
“These data are important for patients who experience chronic insomnia because they demonstrate there is a treatment option in AMBIEN CR that can be taken safely and effectively as needed long-term to help them both fall asleep and maintain sleep through the night,” said Tom Roth, PhD, director of the Sleep Disorders Center at Henry Ford Hospital in Detroit Mich.
The results from the study that demonstrated AMBIEN CR is well-tolerated and effective in improving sleep onset and maintenance for up to 6 months in patients with chronic primary insomnia when taken as needed for up to 7 nights per week, without rebound insomnia following discontinuation.
Data from this study was presented on July 12 in Chicago at the CINP (Collegium Internationale NeuroPsychopharmacologicum) 25th Biennial Congress, a meeting ground for clinicians and scientists to report new scientific evidence in biochemistry, pharmacology, safety, and therapeutic efficacy of neuropsychiatric drugs.